Rheumatoid Arthritis Diagnosis and Treatment

Diagnostic Laboratory Tests

The American College of Rheumatology recommends Erythrocyte Sedimentation Rate (ESR) and C-Reactive Protein (CRP) tests at baseline for diagnostic and prognostic purposes in patients with suspected Rheumatoid Arthritis (RA) 1, 2
Rheumatoid Factor (RF) testing is essential for RA diagnosis and prognosis, as recommended by the European League Against Rheumatism 1, 2
Anti-Citrullinated Protein Antibodies (ACPA/anti-CCP) testing has higher specificity (90%) for RA than RF and provides important prognostic information, according to the American College of Rheumatology 1, 2, 3
The presence of RF and/or ACPA significantly increases the probability of developing RA, as stated by the American College of Rheumatology 2
High-positive RF or ACPA carries more diagnostic weight (3 points) than low-positive results (2 points) in the 2010 ACR/EULAR Classification Criteria, as recommended by the American College of Rheumatology and the European League Against Rheumatism 4, 5

X-rays of hands, wrists, and feet should be performed at baseline to predict the development of RA and persistence of disease, as recommended by the European League Against Rheumatism 2
X-rays should be repeated within 1 year in case of disease persistence, according to the European League Against Rheumatism 2
Ultrasound or MRI may be helpful to detect subclinical inflammation when clinical examination is inconclusive, as stated by the American College of Rheumatology 3

For mild disease (Grade 1), NSAIDs and acetaminophen may be used for symptom control, as recommended by the American Society of Clinical Oncology 6
For moderate disease (Grade 2) inadequately controlled with NSAIDs, initiate prednisone 10-20 mg/day or equivalent, as recommended by the American Society of Clinical Oncology 6
If unable to lower corticosteroid dose below 10 mg/day after 6-8 weeks, consider adding a DMARD, according to the American Society of Clinical Oncology 6
For severe disease (Grade 3-4), initiate oral prednisone 0.5-1 mg/kg and consider synthetic or biologic DMARDs, as recommended by the American Society of Clinical Oncology 6

Patients should be monitored with serial rheumatologic examinations, including inflammatory markers, every 4-6 weeks after treatment initiation, as recommended by the American Society of Clinical Oncology 6
Use composite disease activity measures such as DAS28, SDAI, or CDAI to guide treatment decisions, according to the American College of Rheumatology and the European League Against Rheumatism 3, 7

The patient is experiencing active synovitis in wrists and fingers despite being on a regimen that includes hydroxychloroquine 200mg daily 8
The recent knee joint injection with triamcinolone was appropriate for localized inflammation 8
The patient has active disease with pain and swelling in wrists and fingers, indicating a need for optimized DMARD therapy 9

Increase methotrexate dose to 20-25mg weekly or maximum tolerated dose, and consider switching to subcutaneous administration for better bioavailability 8
Consider intra-articular glucocorticoid injections for the affected wrist and finger joints 8
If the patient continues to have moderate to high disease activity despite optimized therapy, consider ensuring triple DMARD therapy is optimized or switching to an alternative biologic agent 8
Rituximab may be particularly effective given the patient's seropositivity for RF and Anti-CCP 8

Subcutaneous MTX has better bioavailability than oral administration in patients with inadequate response 8
The treat-to-target approach with a goal of remission or low disease activity improves long-term outcomes 8
Inadequate response to current therapy after 3-6 months indicates need for treatment modification 8

The British Medical Journal recommends testing for rheumatoid factor (RF) in all patients with suspected rheumatoid arthritis who present with synovitis, and adding anti-cyclic citrullinated peptide (anti-CCP) antibody testing if RF is negative or when considering combination therapy, as 30-40% of RA patients may be RF-negative 10, 11
The British Medical Journal suggests measuring anti-CCP in RF-negative patients and when combination therapy is being considered, as anti-CCP provides important prognostic information 10, 11, 12, 13

Refer urgently for specialist evaluation even with normal acute-phase response or negative RF if small joints of hands or feet are affected, more than one joint is affected, or there is a delay of 3 months or longer between symptom onset and seeking medical advice 10, 11, 12, 13

The Mayo Clinic Proceedings target is remission or low disease activity within 6 months, and this can be achieved with composite disease activity measures (DAS28, SDAI, or CDAI) every 4-6 weeks after treatment initiation 14